Patents Represented by Attorney, Agent or Law Firm A. David Joran
-
Patent number: 8309716Abstract: This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.Type: GrantFiled: June 20, 2012Date of Patent: November 13, 2012Assignee: Pfizer Inc.Inventors: Sally Gut Ruggeri, Joel M Hawkins, Teresa M Makowski, Jennifer L Rutherford, Frank J Urban
-
Patent number: 8232394Abstract: This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.Type: GrantFiled: July 17, 2006Date of Patent: July 31, 2012Assignee: Pfizer Inc.Inventors: Sally Gut Ruggeri, Joel M. Hawkins, Teresa M. Makowski, Jennifer L. Rutherford, Frank J. Urban
-
Patent number: 8222273Abstract: The present invention relates to a polymorphic form B of ?/-[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl]-N-{2-[(3-{2-[(2-hydroxyethyl)sulfanyl]phenyl}[1,2,4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]benzyl}urea (I) as de-fined herein. This polymorph is useful in the treatment of various conditions, particularly in the treatment of inflammatory conditions such as chronic obstructive pulmonary disease.Type: GrantFiled: January 28, 2009Date of Patent: July 17, 2012Assignee: Pfizer LimitedInventor: Kenneth John Butcher
-
Patent number: 8076356Abstract: A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.Type: GrantFiled: February 16, 2009Date of Patent: December 13, 2011Assignee: Pfizer Inc.Inventors: John Paul Mathias, David Simon Millan, Russell Andrew Lewthwaite, Christopher Phillips
-
Patent number: 7897733Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.Type: GrantFiled: November 14, 2005Date of Patent: March 1, 2011Assignee: Pfizer, Inc.Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
-
Patent number: 7786097Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: July 21, 2009Date of Patent: August 31, 2010Assignee: Pfizer Inc.Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Patent number: 7767850Abstract: A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arranged as generally orderly packed agglomerates, which are particularly useful in making pharmaceutical compositions. Such pharmaceutical compositions are also described, as well as methods to make crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, and methods of treating conditions characterized by an overexpression on nitric oxide from the inducible isoform of nitric oxide synthase using the S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.Type: GrantFiled: December 5, 2008Date of Patent: August 3, 2010Assignee: Pfizer Inc.Inventors: Lyle Brostrom, Ann Czyzewski, Vahid Zia, Ahmad Sheikh
-
Patent number: 6924289Abstract: The present invention relates to lactam derivatives of the formula wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for their preparation, and to their medicinal use as selective agonists and antagonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. These compounds are useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.Type: GrantFiled: August 15, 2002Date of Patent: August 2, 2005Assignee: Pfizer IncInventor: Harry R. Howard
-
Patent number: 6825193Abstract: The present invention is directed to a polymorph of the citrate salt of 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one: and pharmaceutical compositions thereof.Type: GrantFiled: December 6, 2002Date of Patent: November 30, 2004Assignee: Pfizer Inc.Inventors: George J. Quallich, Lewin T. Wint
-
Patent number: 6727283Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.Type: GrantFiled: October 11, 1999Date of Patent: April 27, 2004Assignee: Pfizer Inc.Inventors: Nancy J. Harper, Gautam R. Ranade, Willard M. Welch
-
Patent number: 6706702Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: August 13, 2002Date of Patent: March 16, 2004Assignee: Pfizer Inc.Inventor: Jotham Wadsworth Coe
-
Patent number: 6624313Abstract: A process of preparing compounds having the formula I: or an optical isomer or racemic or optically active mixture thereof, which are useful as selective kappa-receptor agonists.Type: GrantFiled: April 26, 2002Date of Patent: September 23, 2003Assignee: Warner-Lambert Company LLCInventors: Keith M. DeVries, Michel A. Couturier, Brian M. Andresen, John L. Tucker, Fumitaka Ito
-
Patent number: 6593496Abstract: This invention relates to a novel improved process for preparing the (+) enantiomer of N-[4(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine by reacting the (+) enantiomer of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone with monomethylamine and titanium chloride or molecular sieves.Type: GrantFiled: May 30, 2000Date of Patent: July 15, 2003Assignee: Pfizer IncInventor: George H. Quallich
-
Patent number: 6531468Abstract: The present invention provides diazabicyclooctane derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein the group represents R1 and R2 are selected independently from H, (C1-C6)alkyl, (C1-C6)fluoroalkyl, halogen (e.g., F.Type: GrantFiled: August 1, 2001Date of Patent: March 11, 2003Assignee: Pfizer IncInventors: Anton Franz Joseph Fliri, Randall James Gallaschun
-
Patent number: 6410032Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by the method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.Type: GrantFiled: October 31, 2000Date of Patent: June 25, 2002Assignee: Pfizer IncInventors: Xuemei Cao, Michael G. Sheppard
-
Patent number: 6387941Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R2 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR9, —CO2R9, —CONR9R10, —OR9, —SO2NR(R10, or —S(O)4R8; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 C3 alkyl; R11 is hydrogen, —Or12, or —NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkyl-Type: GrantFiled: October 23, 2000Date of Patent: May 14, 2002Assignee: Pfizer Inc.Inventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6387937Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 ; alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R3 are each independently hydrogen, Cl1 to C8 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR8, —CO2R9, —CONR9R10, —OR8, —SO2NR8R10, or —S(O)4R9; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, —OR12, or —NHCOR12; R12 is hydrogen, C1 to C4 alkyl, aryl, or C1 to C3Type: GrantFiled: October 23, 2000Date of Patent: May 14, 2002Assignee: Pfizer Inc.Inventors: John Eugene Macor, Martin James Wythes
-
Patent number: 6380204Abstract: The present invention relates to novel atropisomers of 3-heteroaryl-4(3H)-quinazolinones of the formula Ia, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.Type: GrantFiled: January 13, 2000Date of Patent: April 30, 2002Assignee: Pfizer INCInventors: Bertrand Leo Chenard, Keith Michael Devries, Willard McKowan Welch, Jr.
-
Patent number: 6380226Abstract: A crystalline, &bgr;-polymorphic form of a compound of formula (I):Type: GrantFiled: June 15, 2000Date of Patent: April 30, 2002Assignee: Pfizer IncInventors: Valerie Denise Harding, Ross James Macrae, Ronald James Ogilvie
-
Patent number: 6380233Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R3 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR8, —CO2R8, —CONR8R10, —OR9, —SO2NR9R10, or —S(O)4R8; R8 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 to C3 alkyl; R11 is hydrogen, —OR12, or —NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkType: GrantFiled: October 23, 2000Date of Patent: April 30, 2002Assignee: Pfizer IncInventors: John Eugene Macor, Martin James Wythes